ABCC9 and type 2 diabetes mellitus: The growing prevalence of type 2 diabetes has been a major driving force in the pharmaceutical industry for creating drugs that are highly selective for SUR1 over SUR2, leaving the state of SUR2 pharmacology virtually undeveloped.